The Penumbra SwiftPAC™ Coil, part of the company’s Swift™ Coil System, is designed for endovascular occlusion of vascular anomalies such as aneurysms and fistulas.
The device received the CE mark in September 2025, authorising its commercial use across Europe.
Recommended Buyers Guides
SwiftPAC joins Penumbra’s neuro embolisation portfolio, which also includes the PC400™ System, Swift™ Coil System, POD400™ and PAC400™, ACCESS25™ Delivery Microcatheter, PX SLIM™ Delivery Microcatheter, and SMART COIL® System.
Clinical applications of SwiftPAC
SwiftPAC is indicated for embolisation procedures, including treatment of carotid cavernous fistulas, middle meningeal artery (MMA) embolisation, and coiling of small aneurysms.
Penumbra positions the coil for scenarios where high conformability and precise repositioning are required, and as an option that may mitigate some risks associated with liquid embolic agents in MMA by reducing unintended passage through anastomoses.
Chronic subdural haematoma is the most frequent neurosurgical condition among older adults and is projected to become the leading cranial surgical disorder by the end of the decade.
MMA embolisation has emerged as a strategy to reduce recurrence in chronic subdural haematoma and could materially change management in elderly patients.
Estimates indicate annual MMA embolisation procedures for older adults could exceed 140,000, surpassing endovascular volumes for large-vessel stroke.
SwiftPAC is positioned to support clinicians as MMA embolisation volumes grow, combining coil-based operational efficiency with high-conformability occlusion characteristics.
SwiftPAC Coil specifications and features
SwiftPAC is supplied as a single-use, disposable handle and is compatible with 0.0165in (10-System) delivery microcatheters.
The coil has a primary diameter of 0.0135in (0.343mm) and is available in lengths from 3cm to 60cm to accommodate a range of vessel sizes and anatomies.
Penumbra reports a softness value of 0.093, positioning SwiftPAC among the softest coils designed for the 10-system class.
The device features instant mechanical detachment and supports accurate placement with the ability to reposition prior to release.
Designed to function similarly to a “liquid metal”, the coil’s two-dimensional (2D) sinusoidal (wave) shape is intended to conform to the target lumen and improve packing density.
Additionally, the device incorporates the company’s Ultra HD Fibre, which offers stretch resistance and increased flexibility and strength compared with traditional polypropylene materials.
Early clinical experience
A single-centre case series led by neurosurgeon Nicolas Khattar at the University of Tennessee Health Science Center Semmes Murphey Clinic evaluated SwiftPAC in 18 consecutive embolisation procedures for various neurovascular conditions.
Complete target vessel occlusion was attained in all but one case, where vasospasm impeded coil deployment.
An average of seven coils (range 1–22) were used per case, and no complications were reported in the cohort.
The authors noted that the 2D wave configuration aided distal advancement in tortuous anatomy where the microcatheter could not reach further segments, and that the broad length range may reduce the total number of coils required.
The series suggests potential for shortened procedure times and cost efficiencies, though larger, controlled studies are needed to validate these observations.
Marketing commentary on Penumbra
Founded in 2004, Penumbra is headquartered in Alameda, California, US. It is a thrombectomy company developing solutions for challenging medical conditions, including venous thromboembolism, ischemic stroke, and acute limb ischemia.
The company’s product line, which features computer-assisted vacuum thrombectomy (CAVT), is dedicated to the removal of blood clots.
Penumbra employs over 4,500 staff members and operates in more than 100 worldwide markets.